Showing posts with label Glaucoma. Show all posts
Showing posts with label Glaucoma. Show all posts

Thursday, December 02, 2010

Electrical Activity of Retina May Detect Early Stage Glaucoma.


A test that measures the function of nerve cells in the retina may detect glaucoma at an early stage and help doctors evaluate the effectiveness of treatments, according to a study conducted by Dr Sehi and colleagues at the Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine.

The study was based on the knowledge that retinal ganglion cells (RGCs) become dysfunctional as glaucoma progresses and that such changes can be measured using the pattern electroretinogram optimized for glaucoma screening (PERGLA). PERGLA measures the electrical activity of a patient's retina as he or she views an alternating pattern of black and white lines.

In a study of 47 people with glaucoma who had surgery because their intraocular pressure could not be controlled by medications the test was able to show reversal of RGC dysfunction and reduced intraocular pressure after the operations. Dr. Sehi says these results should be interpreted cautiously until confirmed by larger studies. She calls for longitudinal studies to clarify the relationship between reduced IOP and increased RGC response and to further investigate PERGLA assessment of RGC dysfunction as a biomarker for glaucoma.
Enhanced by Zemanta

Wednesday, August 04, 2010

BMI and Glaucoma

MedPage Today reported, Women with higher body mass index and weight were at reduced risk of developing certain forms of glaucoma, according to a study published in the August issue of Ophthalmology.

In fact, for each unit of body mass index, participants in the giant Nurses' Health Study showed a 6% reduction (95% CI 2% to 9%) in the rate of developing primary open-angle glaucoma with an intraocular pressure of 21 mm Hg or less at diagnosis (so-called normal tension). The study authors theorized that some measure linked to adiposity or lean mass that is under sex hormonal influences may protect against the development of primary open-angle glaucoma.

According to the researchers' report online in Ophthalmology, no relationship between body composition measures and glaucoma risk was found for men in another large cohort, the Health Professionals Follow-Up Study. Nor did BMI or other anthropometric parameters in Nurses' Health Study participants affect the risk of primary open-angle glaucoma with higher intraocular pressure.
Enhanced by Zemanta

Tuesday, May 11, 2010

A great series of tutorials

Here is a video that describes the theory and practical use of Goldman Tonometry. Excellent resource for pre-testing staff and for students.

Wednesday, April 21, 2010

Monitoring May Be Enough For Some Patients At Risk For Glaucoma

Dallas Morning News reported that most patients who are at risk of developing glaucoma because of high eye pressure may just require monitoring.

In a 15-year study presented at the American Glaucoma Society's annual meeting and published in the Archives of Ophthalmology, participants with elevated eye pressure but no evidence of glaucoma were randomized to eye drops or were simply monitored.

In the second part of the study, during which all participants received eye drops, researchers found that in lower-risk patients there was not much difference between those taking drops the whole time and those who got drops seven years later.

Tuesday, February 23, 2010

WV Bill Would Allow Optometrists To Perform Laser Surgeries For Glaucoma





Reported in the Charleston Gazette: As amended in the" West Virginia Senate on Feb. 22, SB230, a controversial bill to allow optometrists to perform specified surgical procedures, would let optometrists perform three types of laser surgery to treat glaucoma.
While opponents of the bill such as Sen. Ron Stollings, D-Boone argued Monday that's three procedures too many.
Stollings, a physician in Madison, said he became ill undergoing one of the laser surgery procedures for glaucoma, and considers himself fortunate he was under the care of an ophthalmologist -- a medical doctor with advanced training in treatment of eye diseases -- rather than an optometrist.
Senate Judiciary Chairman Jeff Kessler (D-Marshall), who offered the amendment on the Senate floor, said there are safeguards built into the proposed legislation.
The bill went through the Government Organization Committee, but bypassed the Health and Human Resources Committee. The Register-Herald quotes optometrist David Holliday, OD, saying, "Optometrists are performing these procedures in certain states. We're not the exception by any means. We feel comfortable with those procedures and fully qualified to do those jobs
Reblog this post [with Zemanta]

Monday, September 21, 2009


Merck amp; Co., Inc. has launched SAFLUTAN® (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today.

SAFLUTAN is a preservative free, synthetic analogue of the prostaglandin F2α for the reduction of elevated intraocular pressure (IOP) in appropriate patients with primary open-angle glaucoma and ocular hypertension. SAFLUTAN is in Phase III in the U.S.

Merck amp; Co., Inc. which operates in many countries as Merck Sharp amp; Dohme or MSD, and Santen Pharmaceutical Co., Ltd. announced a worldwide licensing agreement for tafluprost. Under the terms of the agreement, Merck agreed to pay an undisclosed fee as well as milestones and royalty payments based on future sales of tafluprost (both preserved and preservative-free formulations) in exchange for exclusive commercial rights to tafluprost in western Europe (excluding Germany), North America, South America and Africa. Santen will retain commercial rights to tafluprost in most countries in eastern Europe, northern Europe and in countries in the Asia Pacific area, including Japan. Merck will provide promotion support to Santen in Germany and Poland. If tafluprost is approved in the U.S., Santen will have the option to co-promote it there. SAFLUTAN marketed by MSD, and TAFLOTAN®, marketed by Santen in respective territories, is the only preservative-free prostaglandin currently available for patients with glaucoma.

Reblog this post [with Zemanta]

Thursday, July 16, 2009

Glaucoma surgeries up while Medicare reimbursement down

According to a study published in the July issue of the Archives of Ophthalmology, the number of glaucoma surgeries is on the rise, but Medicare reimbursement for the procedures has been decreasing.

For the study, researchers from Exponent, Alcon Research, and the Bloomberg School of Public Health analyzed Part B Medicare data for 100,000 beneficiaries from 1997 to 2006. The team found that from 1997 to 2001, there was an overall decrease in both the number of procedures and the amount of annual payments, but there was an increase in the number of procedures in the following years, reaching a total of 414,980 in 2006. The investigators attributed the increase to advancements in technology and a change in calculating the global period for reimbursement purposes.

The authors also noted that payments for trabeculectomies decreased over time, while annual payments for newer procedures, such as cyclophotocoagulation and shunt-related procedures, have increased.

Reblog this post [with Zemanta]

A new paradigm for understanding glaucoma has emerged

Glaucoma isn't simply an eye disease, experts now say, but rather a degenerative nerve disorder, not unlike Alzheimer's or Parkinson's disease.

While researchers still recognize high pressure within the eye as a leading risk factor for glaucoma, it is becoming clear that the condition begins with injury to the optic nerve as it exits the back of the eye. The damage then spreads, moving from one nerve cell to adjoining nerve cells.

Neeru Gupta, MD, PhD, of the University of Toronto, explained, In glaucoma, we've shown that when your retinal ganglion cells are sick, the long axons that project from the eye into the brain are also affected, resulting in changes that we can detect in the vision center of the brain. This phenomenon, called transynaptic damage, occurs in Alzheimer's and Parkinson's disease, as well.

Reblog this post [with Zemanta]

Friday, February 13, 2009



Illinois' Belleville News Democrat (2/12) reported that a new device called the Trabectome speeds glaucoma operations and post-surgical recovery.

The device works by reducing pressure in the eye without the need for the filtration or shunts used in traditional glaucoma surgery, allowing surgeons to remove tissue so fluid more easily drains out of the eye. While traditional glaucoma surgery usually means several weeks of recovery with no lifting or bending, the recovery with the Trabectome normally takes about a week. But, not all glaucoma patients...are good candidates for the new device. According to glaucoma researcher Carla J. Siegfried, M.D., patients in the early to moderate stages of the disease are the best candidates

Thursday, January 29, 2009

Cataracts are the most common age-related eye disease, with more than 17 percent of Americans age 40 and over affected. The main cause, aside from plain old aging, is exposure to ultraviolet B radiation in sunlight. People can reduce their risk and delay the need for surgery to remove a clouded lens by wearing sunglasses and brimmed hats while outside.

At present, cataract surgery has been refined so that the super small incisions are self-sealing. Besides cataracts, eye conditions such as glaucoma and macular degeneration also affect seniors, although they are more insidious. Typically, medications are used to slow the damage caused by glaucoma. Meanwhile, high doses of supplements, including vitamins C and E and beta carotene and the mineral zinc, have been found to slow the progression of AMD in several trials.

This report was published in the US News and World Report

It was also noted that people with diabetes have added reason to worry: Diabetic retinopathy affects some 40 percent of people with the disease, with 8 percent of all diabetics facing significant vision loss. Keeping your blood sugar levels under control reduces the risk of harm.

Wednesday, January 28, 2009

Glaucoma Associated With Reading Impairments in Elderly

A study by the Johns Hopkins University’s Wilmer Eye Institute found people with glaucoma in both eyes (bilateral) read 29 words per minute slower than those without glaucoma. They also were almost twice as likely to have reading impairment.

Those with glaucoma in one eye (unilateral) had rates about on par with those without the condition, which can cause eye damage and vision loss.

The findings were published in the January issue of Archives of Ophthalmology.

Thursday, December 11, 2008

Diabetes-related eye diseases may skyrocket over next four decades

The New York Times reports that, according to a study published Dec. 9 in the Archives of Ophthalmology, diabetes-related eye diseases will skyrocket over the next four decades, with elderly Hispanics and blacks hit hardest because of higher rates of Type 2 diabetes.

In particular, the report projects that the number of adults 40 and older with diabetic retinopathy -- the leading cause of blindness among working-age adults -- will reach 16 million in 2050, up from 5.5 million in 2005. In addition, the study estimates that the number of diabetics with glaucoma will quadruple to 1.4 million, while the number with cataracts will more than triple to 10 million. Study author Jinan B. Saaddine, M.D., M.P.H., of the Centers for Disease Control and Prevention (CDC), said the findings are a call for to do more to prevent diabetes to start with.

Thursday, July 10, 2008

Smart contact lens feels the pressure of glaucoma




New Scientist reported, "A contact lens with a built-in pressure sensor that could help monitor" certain eye conditions was recently designed by scientists at the University of California-Davis. Using polydimethylsiloxane, "an elastic, transparent, and gas-permeable organic polymer," the researchers produced "a tiny pressure sensor, which they bent into the shape of a contact lens. Such a device could measure the stress on the cornea surface, and the fluid pressure within the eye to monitor glaucoma and ocular hypertension." Researcher Tingrui Pan explained that in glaucoma patients, rising pressure within the eye changes its shape, "which would deform the contact lens sensor." A prototype model "has an opaque sensor that would impair vision, and so would be worn only briefly," but the research team is "designing transparent equivalents that could be worn for long periods to give a continuous pressure read-out."

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review